M. Bafadhel (Oxford (Oxfordshire), United Kingdom), G. Brusselle (Ghent, Belgium)
This session is built from abstracts published on the ERS Congress platform from 23 August, in a PowerPoint format with a pre-recorded audio narration. The live session is scheduled from September 5-7 and each presenter will have a 5-minutes live, slide show presentation followed at the end of the session by 30-minutes general discussion.
Ten-year projected outcomes associated with increased use of triple therapies in UK patients with COPD using the COPD Health Outcome Policy and INtervention (CHOPIN) model
E. de Nigris (Cambridge, United Kingdom), P. Mcewan (Cardiff, United Kingdom), U. Holmgren (Gothenburg, Sweden), J. Marshall (Cambridge, United Kingdom), H. Müllerová (Cambridge, United Kingdom), V. Foos (Cardiff, United Kingdom)
|    |
COPD maintenance therapy is related to left heart size: Results from the multicenter long-term observation COSYCONET
P. Alter (Marburg, Germany), C. Kellerer (Munich, Germany), K. Kahnert (Munich, Germany), F. Trudzinski (Heidelberg, Germany), J. Lutter (Munich, Germany), K. Berschneider (Nuremberg, Germany), T. Speicher (Marburg, Germany), H. Watz (Grosshansdorf, Germany), R. Bals (Homburg, Germany), T. Welte (Hannover, Germany), C. Vogelmeier (Marburg, Germany), R. Jörres (Munich, Germany)
| |
Effect of high or low-medium accumulated dose regimes of systemic corticosteroids for hospitalised patients with exacerbated chronic obstructive pulmonary disease: pooled analysis of individual participant data from the REDUCE and CORTICO-COP trials
P. Sivapalan (Hellerup, Denmark), J. Rutishauser (Baden, Basel, Switzerland), C. Ulrik (Hvidovre, Denmark), J. Leuppi (Basel, Liestal, Switzerland), L. Pedersen (Copenhagen, Denmark), B. Mueller (Liestal, Aarau, Switzerland), J. Eklöf (Hellerup, Denmark), T. Biering-Sørensen (Hellerup, Copenhagen, Denmark), V. Gottlieb (Hellerup, Denmark), K. Armbruster (Hellerup, Denmark), J. Janner (Hvidovre, Denmark), M. Moberg (Hvidovre, Denmark), T. Lapperre (Antwerp, Belgium), T. Nielsen (Hillerød, Denmark), A. Browatzki (Hillerød, Denmark), A. Mathiousdakis (Manchester, United Kingdom), J. Vestbo (Manchester, United Kingdom), P. Schüetz (Basel, Aarau, Switzerland), J. Jensen (Hellerup, Denmark)
| |
Are patients with COPD more adherent to single-inhaler compared with multiple-inhaler triple therapy in a real-world UK primary care treated population?
K. Rothnie (London, United Kingdom), A. Czira (London, United Kingdom), C. Compton (London, United Kingdom), V. Banks (Bollington, United Kingdom), R. Wood (Bollington, United Kingdom), T. Tritton (Bollington, United Kingdom), J. Thomas (Bollington, United Kingdom), O. Massey (Bollington, United Kingdom), S. Blackburn (Bollington, United Kingdom), R. Wild (Bollington, United Kingdom), A. Ismaila (Upper Providence, United States of America)
| |
The therapeutic potential of PD-1/PD-L1 blockade in smoking exposed emphysema
J. Kim (Seoul, Republic of Korea), N. Kim (Seoul, Republic of Korea), C. Shon (Seoul, Republic of Korea), J. Huh (Seoul, Republic of Korea), K. Han (Seoul, Republic of Korea), K. Kim (Suwon, Republic of Korea), S. Shin (Seoul, Republic of Korea), H. Park (Seoul, Republic of Korea), S. Lee (Seoul, Republic of Korea)
| |
Epigenetic regulation via PRMT7 controls monocyte migration and COPD pathogenesis
T. Conlon (München, Germany), G. Gunes (München, Germany), A. Jeridi (München, Germany), R. Kim (München , Germany), G. Burgstaller (München, Germany), S. Verleden (Leuven , Belgium), T. Stöger (München , Germany), G. Dittmar (Luxembourg, Luxembourg), M. Königshoff (München , Germany), O. Eickelberg (Denver, United States of America), H. Watz (Großhansdorf, Germany), R. Schneider (München , Germany), A. Yildirim (München , Germany)
| |
COPD exacerbation and use of methotrexate – a nationwide study of 58,580 outpatients
C. Bergsøe (Hellerup, Denmark), P. Sivapalan (Roskilde, Denmark), J. Eklöf (Hellerup, Denmark), Z. Saghir (Hellerup, Denmark), R. Sørensen (Hellerup, Denmark), M. Saeed (Hellerup, Denmark), J. Jensen (Copenhagen, Denmark)
| |
Relationship between prior triple therapy use and benefits of budesonide/glycopyrronium/formoterol on exacerbation risk: analysis from ETHOS
D. Singh (Manchester, United Kingdom), K. Rabe (Grosshansdorf, Germany), F. Martinez (New York, NY, United States of America), M. Jenkins (Cambridge, United Kingdom), M. Patel (Cambridge, United Kingdom), P. Dorinsky (Durham, NC, United States of America)
| |
Late Breaking Abstract - Comparing pneumonia risk in COPD patients initiating Fixed Dose Combination (FDC) inhaler comprising extrafine beclometasone dipropionate versus fluticasone
D. Price (Singapore, Singapore), W. Henley (Singapore, Singapore), V. Carter (Singapore, Singapore), D. Skinner (Singapore, Singapore), R. Vella (Singapore, Singapore), A. Papi (Ferrara, Italy), L. Fabbri (Ferrara, Italy), H. Kerstjens (Groningen, Netherlands), N. Roche (Paris, France), D. Singh (Manchester, United Kingdom), C. Vogelmeier (Marburg, Germany), E. Sen (Ankara, Turkey), J. Cançado (São Paulo, Brazil), E. Nudo (Parma, Italy), S. Barile (Parma, Italy), G. Georges (Parma, Italy)
| |
Late Breaking Abstract - The TRITRIAL COPD study: preliminary baseline patient characteristics collected during the COVID-19 pandemic
P. Schino (Acquaviva delle Fonti (BA), Italy), E. Bargagli (Siena, Italy), A. Ricci (Rome, Italy), F. Marchesani (Macerata, Italy), A. Pennisi (Gravina di Catania (CT), Italy), A. Camiciottoli (Florence, Italy), A. Rocca (Bologna, Italy), M. D'Amato (Naples, Italy), F. Macagno (Rome, Italy), E. Ingrassia (Parma, Italy), U. Scaffidi Argentina (Parma, Italy), A. Piraino (Parma, Italy), L. Richeldi (Rome, Italy)
| |
Discussion
| |